Evidence map›Paper›PMID 34606114›Full record

Trial reportActa paediatrica (Oslo, Norway : 1992)2022

Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children.

Giacomo Casabona, Md Ahsan Habib, Michael Povey, Marianne A Riise Bergsaker, Carl-Erik Flodmark, Ketil Arne Espnes, Camilla Tøndel, Sven-Arne Silfverdal

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Acta paediatrica (Oslo, Norway : 1992), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Giacomo CasabonaGSK, Wavre, Belgium.ORCID https://orcid.org/0000-0002-3577-8969
Md Ahsan HabibGSK, Wavre, Belgium.
Michael PoveyGSK, Wavre, Belgium.
Marianne A Riise BergsakerThe Norwegian Institute of Public Health, Oslo, Norway.
Carl-Erik FlodmarkDepartment of Paediatrics, Skåne University Hospital, Malmö, Sweden.ORCID https://orcid.org/0000-0001-9705-4766
Ketil Arne EspnesRisvollan Legesenter, Trondheim, Norway.
Camilla TøndelDepartment of Paediatrics, Haukeland University Hospital, Bergen, Norway.
Sven-Arne SilfverdalDepartment of Clinical Sciences, Paediatrics, Umeå University, Umeå, Sweden.ORCID https://orcid.org/0000-0002-3606-3797
GlaxoSmithKline (Belgium) · BEArchäologischen Dienst Graubünden · CHHaukeland University Hospital · NONorwegian Institute of Public Health · NOSkåne University Hospital · SEUmeå University · SE

Funding

GlaxoSmithKline Biologicals SA
6 · The paper itself

Abstract

aimSeveral countries, such as Norway and Sweden, have not implemented universal varicella vaccination. We present data for Norway and Sweden that were generated by a paediatric multi-country Phase III study over a 10-year period. This assessed the efficacy, antibody persistence and safety of two varicella vaccines containing the same Oka strain.

methodsThis was an observer-blind, controlled trial conducted in 10 European countries. Children aged 12-22 months (n = 5803) were randomised 3:3:1 and vaccinated between 1 September 2005 and 10 May 2006. The two-dose group received two tetravalent measles-mumps-rubella-varicella vaccine doses. The one-dose group received one monovalent varicella vaccine dose after a measles-mumps-rubella vaccine dose. Control group participants received two measles-mumps-rubella vaccine doses. Main study outcomes were vaccine efficacy against confirmed varicella cases and incidence of adverse events.

resultsVaccine efficacy in the two-dose group was ≥92.1% in both Norwegian and Swedish children compared to 72.3% in Norway and 58.0% in Sweden in the one-dose group. Incidences of adverse events and serious adverse events were similar in the Norwegian and Swedish study populations.

conclusionConsistent with overall study results, high efficacy against varicella and acceptable safety profiles of the two varicella vaccines were observed in Norwegian and Swedish populations. These findings highlight the benefits of varicella vaccines, particularly when administered as a two-dose schedule.

Indexed as

ChickenpoxAntibodies, ViralChickenpox VaccineChildHumansInfantMeasles-Mumps-Rubella VaccineNorwaySwedenVaccine EfficacyAntibodies, ViralChickenpox VaccineMeasles-Mumps-Rubella VaccineefficacyNorwaysafetySwedenvaricella vaccine

Identifiers

PMID34606114
PMCPMC9297935
OpenAlexW3202596318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.